Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr;201(2):185-198.
doi: 10.1111/bjh.18697. Epub 2023 Feb 20.

How I manage mantle cell lymphoma: indolent versus aggressive disease

Matthew R Wilson  1 , Aisling Barrett  2 , Chan Yoon Cheah  3   4 , Toby A Eyre  2
Affiliations
Review

How I manage mantle cell lymphoma: indolent versus aggressive disease

Matthew R Wilson et al. Br J Haematol. 2023 Apr.

Abstract

Mantle cell lymphoma (MCL) is a mature B-cell lymphoma with a variable clinical course and historically poor prognosis. Management is challenging in part due to the heterogeneity of the disease course, with indolent and aggressive subtypes now well recognised. Indolent MCL is often characterised by a leukaemic presentation, SOX11 negativity and low proliferation index (Ki-67). Aggressive MCL is characterised by rapid onset widespread lymphadenopathy, extra-nodal involvement, blastoid or pleomorphic histology and high Ki-67. Tumour protein p53 (TP53) aberrations in aggressive MCL are recognised with clear negative impact on survival. Until recently, trials have not addressed these specific subtypes separately. With the increasing availability of targeted novel agents and cellular therapies, the treatment landscape is constantly evolving. In this review, we describe the clinical presentation, biological factors, and specific management considerations of both indolent and aggressive MCL and discuss current and potential future evidence which may help move to a more personalised approach.

Keywords: chemotherapy; lymphomas; lymphoproliferative disease; non-Hodgkin lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28(10):2489-95.
    1. Kumar A, Ying Z, Alperovich A, Dogan A, Hamlin P, Moskowitz C, et al. Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica. 2019;104(4):e163-6.
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90.
    1. Kimura Y, Sato K, Imamura Y, Arakawa F, Kiyasu J, Takeuchi M, et al. Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. Cancer Sci. 2011;102(9):1734-41.
    1. Hsu P, Yang T, Sheikh-Fayyaz S, Brody J, Bandovic J, Roy S, et al. Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature. Int J Clin Exp Pathol. 2014;7(3):1042-50.

Publication types

LinkOut - more resources